Jingyu Yu

2.8k total citations
27 papers, 1.3k citations indexed

About

Jingyu Yu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jingyu Yu has authored 27 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Jingyu Yu's work include Cancer Immunotherapy and Biomarkers (6 papers), Pharmaceutical studies and practices (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Jingyu Yu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Pharmaceutical studies and practices (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Jingyu Yu collaborates with scholars based in United States, China and Switzerland. Jingyu Yu's co-authors include Richard Pazdur, Gideon M. Blumenthal, Patricia Keegan, Kirsten B. Goldberg, Hong Zhao, Kun He, Sriram Subramaniam, Amy E. McKee, Hongshan Li and Mark Paciga and has published in prestigious journals such as PLoS ONE, Brain and Clinical Cancer Research.

In The Last Decade

Jingyu Yu

23 papers receiving 1.3k citations

Peers

Jingyu Yu
Sofía Braga Portugal
Véronique D’Hondt France
Anna Minchom United Kingdom
Luisa Carbognin Italy
Olaf Christensen United States
Izumi Nagatomo Japan
Filipa Lynce United States
Yu Gu China
Alexios Matikas Sweden
Carsten Grüllich Germany
Sofía Braga Portugal
Jingyu Yu
Citations per year, relative to Jingyu Yu Jingyu Yu (= 1×) peers Sofía Braga

Countries citing papers authored by Jingyu Yu

Since Specialization
Citations

This map shows the geographic impact of Jingyu Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jingyu Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jingyu Yu more than expected).

Fields of papers citing papers by Jingyu Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jingyu Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jingyu Yu. The network helps show where Jingyu Yu may publish in the future.

Co-authorship network of co-authors of Jingyu Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Jingyu Yu. A scholar is included among the top collaborators of Jingyu Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jingyu Yu. Jingyu Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Jingyu, et al.. (2025). Bridge RNA-Guided Genetic Recombination Tools for Treating Neurodegenerative Nucleotide Repeat Disorders. Neuroscience Bulletin. 41(4). 734–736.
2.
Li, Tianwen, Peng Wang, Fengshi Li, et al.. (2025). Engineered neural stem cell vesicles activating Wnt promote blood–brain barrier repair after cerebral haemorrhage. Brain. 149(2). 447–455.
3.
Brave, Michael H., William F. Maguire, Chana Weinstock, et al.. (2024). FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research. 30(21). 4815–4821. 14 indexed citations
4.
Li, Tianwen, Liansheng Zhang, Peng Wang, et al.. (2024). Extracellular vesicles from neural stem cells safeguard neurons in intracerebral hemorrhage by suppressing reactive astrocyte neurotoxicity. Cell Reports. 43(10). 114854–114854. 7 indexed citations
5.
Wang, Li, Jiang Liu, Justin Earp, et al.. (2023). Model‐Informed Approaches to Support Drug Development for Patients With Obesity: A Regulatory Perspective. The Journal of Clinical Pharmacology. 63(S2). S65–S77.
6.
Li, Tianwen, Liansheng Zhang, Tao Lu, et al.. (2023). Engineered Extracellular Vesicle‐Delivered CRISPR/CasRx as a Novel RNA Editing Tool. Advanced Science. 10(10). e2206517–e2206517. 28 indexed citations
7.
Yu, Jingyu, et al.. (2022). Gene Therapy Strategies Targeting Aging-Related Diseases. Aging and Disease. 14(2). 0–0. 29 indexed citations
8.
Li, Shuang, Yichao Tang, Jiali Xiao, et al.. (2022). Preliminary study on the effect of catabolite repression gene knockout on p-nitrophenol degradation in Pseudomonas putida DLL-E4. PLoS ONE. 17(12). e0278503–e0278503. 2 indexed citations
9.
Yu, Jingyu, et al.. (2022). Stereopure AIMer: A Promising RNA Base-editing Tool for Monogenic Neurological Diseases. Neuroscience Bulletin. 39(2). 353–355. 1 indexed citations
10.
Narayan, Preeti, Christy Osgood, Harpreet Singh, et al.. (2021). FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer. Clinical Cancer Research. 27(16). 4478–4485. 118 indexed citations
11.
Bi, Youwei, Jiang Liu, Jingyu Yu, et al.. (2021). Model‐Informed Drug Development in Pediatric Dose Selection. The Journal of Clinical Pharmacology. 61(S1). S60–S69. 17 indexed citations
12.
Chang, Elaine, Chana Weinstock, Lijun Zhang, et al.. (2020). FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research. 27(4). 922–927. 135 indexed citations
13.
Yu, Jingyu, et al.. (2019). Treatment of Chronic Nonbacterial Prostatitis Majorly with Deep Acupuncture at Baliao Points plus Western Medication: A Randomized Controlled Study. 38(12). 1365–1369. 1 indexed citations
14.
15.
Li, Hongshan, et al.. (2018). Semimechanistically Based Modeling of Pembrolizumab Time-Varying Clearance Using 4 Longitudinal Covariates in Patients With Non–Small Cell Lung Cancer. Journal of Pharmaceutical Sciences. 108(1). 692–700. 24 indexed citations
16.
Shah, Anand, Erik Bloomquist, Shenghui Tang, et al.. (2018). FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer. Clinical Cancer Research. 24(13). 2999–3004. 88 indexed citations
17.
Singh, Harpreet, Amanda J. Walker, Laleh Amiri‐Kordestani, et al.. (2018). U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer. Clinical Cancer Research. 24(15). 3486–3491. 75 indexed citations
18.
Pai-Scherf, Lee H., Gideon M. Blumenthal, Hongshan Li, et al.. (2017). FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. The Oncologist. 22(11). 1392–1399. 228 indexed citations
19.
20.
Li, Hongshan, Jingyu Yu, Chao Liu, et al.. (2017). Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. Journal of Pharmacokinetics and Pharmacodynamics. 44(5). 403–414. 115 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sofía Braga Breakdown of academic impact, for papers by Véronique D’Hondt Breakdown of academic impact, for papers by Anna Minchom Breakdown of academic impact, for papers by Luisa Carbognin Breakdown of academic impact, for papers by Olaf Christensen Breakdown of academic impact, for papers by Izumi Nagatomo Breakdown of academic impact, for papers by Filipa Lynce Breakdown of academic impact, for papers by Yu Gu Breakdown of academic impact, for papers by Alexios Matikas Breakdown of academic impact, for papers by Carsten Grüllich
Rankless by CCL
2026